Area of research
Hematology · Molecular Biology
Research interest
Research interests include Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Peptidase Inhibition and Analysis, and Chemokine receptors and signaling.
Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression
Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma
Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
Bone marrow microenvironment–derived signals induce Mcl-1 dependence in multiple myeloma
Development of GLUT4-selective antagonists for multiple myeloma therapy
Discovery and biological characterization of potent myeloid cell leukemia‐1 inhibitors
BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth
Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax
Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax
In Silico Modeling-based Identification of Glucose Transporter 4 (GLUT4)-selective Inhibitors for Cancer Therapy
Determination of multiple human arsenic metabolites employing high performance liquid chromatography inductively coupled plasma mass spectrometry
MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells
Dimethylarsinothioyl Glutathione as a Metabolite in Human Multiple Myeloma Cell Lines upon Exposure to Darinaparsin
Alterations in Glutathione Levels and Apoptotic Regulators Are Associated with Acquisition of Arsenic Trioxide Resistance in Multiple Myeloma